New drug strategy aims to stop tough liver cancers in their tracks
NCT ID NCT05113186
Summary
This study is testing if adding a cancer drug called lenvatinib can improve outcomes for people with a hard-to-treat form of early-stage liver cancer. Patients receive the drug for a short time before and after a procedure that burns or freezes their tumor. The goal is to see if this combined approach better controls the cancer and prevents it from coming back locally within a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NAHON
Bobigny, 93000, France
Conditions
Explore the condition pages connected to this study.